---
document_datetime: 2026-01-14 15:34:29
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/roctavian-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: roctavian-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7786536
conversion_datetime: 2026-01-17 13:35:35.393394
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ROCTAVIAN

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| Variation type II /  | C.I.11 Introduction of, or change(s) to, the | 13/11/2025                          | N/A                                         |                                  | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000294531                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of an updated RMP version 1.6 in order to remove the Biodistribution study investigating vertical transmission of the AAV5 vector in female mice listed as category 3 study in RMP.   |            |     |      |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000309039 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                     | 11/11/2025 |     | SmPC |
| Variation type IB / EMA/VR/0000290374 | B.I.d.1 Change in the re-test period/storage period or storage conditions of the active                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/08/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                     | substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000250212 | - Renewal - Renewal of Marketing Authorisation                                                                                                                                      | 24/07/2025 | 22/08/2025 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for ROCTAVIAN, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUR / EMA/PSUR/0000274464          | - -                                                                                                                                                                                 |            |            | Maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |